These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2007-006081-15||A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, non-...||2011-08-08||bad-data|
|Reported results||2011-000902-24||An open-label, single arm, phase II trial to investigate the safety and efficacy of Sym004 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have fa...||2012-10-08||due-trials|
|Reported results||2013-003829-29||Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects with Metastatic Colorect...||2017-04-26||due-trials|
|Exempt, with results||2015-003047-19||An Open label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy||2018-05-15||not-yet-due|
|Completed, but no date||2016-000621-39||An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients with Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra...||bad-data|
|Ongoing||2016-003912-11||An Open-label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients with Ad...||not-yet-due|
|Completed, but no date Terminated||2018-000618-39||A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Metast...||bad-data|